Hyundai Bioscience Co., Ltd.

KOSDAQ 048410.KQ

Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2023: 39,775,972

Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) is 39,775,972 for the year ending December 31, 2023, a 1.04% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 39,367,474, a 6.64% change year over year.
Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 36,915,792, a 2.79% change year over year.
Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 35,913,621, a 3.67% change year over year.
Hyundai Bioscience Co., Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 34,643,436, a 2.75% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

KOSDAQ: 048410.KQ

Hyundai Bioscience Co., Ltd.

CEO	Jong-Won Choi
IPO Date	Aug. 28, 2002
Location	South Korea
Headquarters	Academic Cooperation Building
Employees	63
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.

Key trends

Past 5 years